Non-drug pain relief start-up Nervomatrix Ltd., announced today that it has received the approval of the Israeli Ministry of Health to initiate a clinical trial in people.
Nervomatrix has developed a medical device for the treatment of lower back pain. The device is based on a combination of scanning and imaging proprietary technologies for localizing peripheral nerve ending with unique neurostimulation technology to treat only the specific areas identified to be the most effective for pain relief.
The device is capable of scanning the entire lower back area in a “single shot”, target nerve endings related to the endorphin mechanism and applying strong, low-rate transcutaneous electrical stimulation to each of the previously targeted nerve endings.
Nervomatrix is part of Netanya-based Targetech Innovation Center. Targetech is owned and managed by a group of investors from the US (GAIP Greater Akron Investing Partners), Canada (ASG Financial Corp.), and Israel.
Nervomatrix CEO Ori Kanner said, “We plan to begin the trial’s first phase, which will include 20 patients, this month."
Published by Globes [online], Israel business news - www.globes-online.com - on June 1, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009